InvestorsHub Logo
Followers 2
Posts 2974
Boards Moderated 0
Alias Born 06/23/2017

Re: Spideyboy post# 9835

Wednesday, 01/24/2018 8:33:35 AM

Wednesday, January 24, 2018 8:33:35 AM

Post# of 44784
Of course they are not partnering on the manufacturing side or giving up any of the IP, prior to commercializations. Would make zero sense. It's the R&D side of the equation in question, and always has been.

Yes CHA was funding that side and THAT is the point of partnering at this stage. Reduces the risk by lowering the amount of cash to get to the finish line. Up front cash, milestone payments, help to ensure you will make it there. You can say they are funded to get one or two approvals. I don't think that's the case at all. Yes ARS, but if that fails or falls through it will be incredibly painful. I don't see CLI getting half enrolled for at least 2 years.

Japan obviously seems to want a Japanese partner before allowing the "fast track" trial to begin. The one needing only 75 people to enrol before allowing conditional marketing. They were given the go ahead on Dec 21, 2015 from the PMDA. Don't you think we would have been able to enrol 75 by now if something was done quicker than this agonizing Sosei deal?

How much credence would it have given to other products in their pipeline having one with at least conditional approval? Maybe there would be some real interest, not just from people they see regularly at trade shows.

But we know nothing on anything to do with this, as well as pretty much anything. No strategy, direction, nada. Last thing we heard was Zami stating there would be no partnerships until phase 2 results were completed on a product.